Student or educator? Sign up with your school email and get 6 months of Pro free.
PreprintCited by 0

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

De novo design of ACE2 based peptide; a potential candidate for COVID-19 therapeutics

Basit, Abdul, Asif, Muhammad, Rehman, Shafiq ur·2021

Abstract

To date, the current Covid-19 pandemic caused by SARS-CoV-2 has infected 99.2 million while killed 2.2 million people throughout the world and is still spreading widely. The unavailability of potential therapeutics against this virus urges to search and development of new drugs. It enters human cells by interacting with ACE2 and Glucose Regulated Protein 78 (GRP78) receptors expressed on human cell surface through utilizing receptor binding domain (RBD) of its Spike glycoprotein. The RBD domain is highly conserved and is also a potential target for blocking its interaction with human cell surface receptors. We extended our previously proposed tACE2 inhibitory peptide approach (that inhibits RBD and ACE2 interaction) to de novo design of shorter peptides. These peptides can selectively bind to RBD with much higher affinities than the cell surface receptors. Thus, these can block all the binding residues required for binding to cell surface receptors. We used selected amino acid regions (21–40 and 65–75) of ACE2 as scaffold for peptide design using EvoDesign. The method mutates the scaffold residues keeping Cα-backbone of the designed mutant fix, while favorable positioning of mutant R group results in increased binding affinity towards its partner protein. Our designed peptides Pep1 showed interactions with RBD covering almost all of its binding residues with significantly higher binding affinity (-13.2 kcal mol− 1) than the wild type receptors. The MD simulation results showed that designed peptides form a stabilized complex with RBD. We suggest that blocking the RBD through de novo designed peptides can serve as a potential candidate for COVID-19 treatment after been experimentally validated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21203/rs.3.rs-175669/v1

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Massively parallel de novo protein design for targeted therapeutics

    Chevalier, A., Silva, D.-A., Rocklin, G. J., Hicks, D. R., Vergara, R., Murapa, P., Bernard, S. M., Zhang, L., Lam, K.-H., Yao, G., et al. (2017) · Nature · doi:10.1038/nature23912 · Cited by 453 · cited 1×

    “De novo protein design is a novel approach used to optimize the binding interface of protein-protein interactions by mutating the residues into favorable mutants which provide new binding interactions with increased binding a nity and preserved secondary structure [17].”
    Method

Show all 1 references

Metadata

Authors
Basit, A., Asif, M., & Rehman, S. U.
Published
2021-03-08
Cited by
0
References
1
Type
Preprint

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: De novo design of ACE2 based peptide; a potential candidate for COVID-19 therapeutics. https://app.cochat.ai/papers/10.21203/rs.3.rs-175669/v1
The paper
Basit, A., Asif, M., & Rehman, S. U. (2021). De novo design of ACE2 based peptide; a potential candidate for COVID-19 therapeutics. https://doi.org/10.21203/rs.3.rs-175669/v1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.